Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Seredyńska J, Bal W, Kozak K, Surus-Hyla A, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P.
Rogala P, et al. Among authors: czarnecka am.
Cancers (Basel). 2022 Apr 24;14(9):2123. doi: 10.3390/cancers14092123.
Cancers (Basel). 2022.
PMID: 35565255
Free PMC article.